
CJC-1295 + Ipamorelin Blend
Pre-blended GHRH analogue (CJC-1295 without DAC) + selective GHRP (Ipamorelin). Standard research synergy preparation.
- Purity
- >99% (each peptide, HPLC)
- Molecular Weight
- CJC-1295: 3367.93 g/mol · Ipamorelin: 711.86 g/mol
- Sequence
- CJC-1295 (mod GRF 1-29): YAibDAIFTQSYRKVLAQLSARKLLQDIMSR · Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2
- CAS Number
- 863288-34-0 (CJC-1295) · 170851-70-4 (Ipamorelin)
- Storage
- Lyophilized −20°C
- Form
- White lyophilized powder
Pre-blended preparation containing CJC-1295 (Modified GRF 1-29, without Drug Affinity Complex) at 2 mg and Ipamorelin at 2 mg per vial. The combination is widely used in growth-hormone axis research to investigate synergistic stimulation of somatotroph pituitary release through dual pathways (GHRH receptor agonism + selective ghrelin/GHSR receptor activation). Research applications: pituitary GH pulse studies, IGF-1 axis investigation in animal models, comparative analysis of mono- vs combined-secretagogue protocols, receptor desensitisation kinetics, and pulsatile-release pharmacodynamic modelling. Supplied as a co-lyophilised sterile powder in a single vial. Reconstitute with bacteriostatic or sterile water. Lyophilised storage: -20°C, 24+ months. Reconstituted: 14-21 days at 2-8°C. Verified by RP-HPLC (each component) and confirmed mass per peptide via ESI-MS.
This product is intended solely for in-vitro laboratory research. Not for human or veterinary use, food, cosmetics, or any clinical application.
